Tag: AI in Healthcare

  • AI, Personalised Medicine and the NHS: Why Innovation Must Reach the Frontline

    AI, Personalised Medicine and the NHS: Why Innovation Must Reach the Frontline

    The UK has long been recognised as a global leader in medical research and life sciences innovation. From pioneering genomics programmes to world-class universities and research institutions, the UK consistently produces breakthroughs in healthcare science.

    However, translating innovation into routine clinical practice within the NHS has often proved far more difficult.

    Recognising this challenge, the House of Lords Science and Technology Committee has recently launched an inquiry into innovation in the NHS, with a particular focus on personalised medicine and artificial intelligence.

    The inquiry aims to explore why many promising healthcare innovations struggle to reach widespread adoption within the NHS, despite the UK’s strong research ecosystem.

    This question sits at the heart of modern healthcare policy.

    The Promise of Artificial Intelligence in Healthcare

    Artificial intelligence is rapidly emerging as one of the most transformative technologies in healthcare. Across the world, AI is being explored in areas such as:

    • medical imaging and diagnostics
    • predictive analytics and risk modelling
    • clinical decision support
    • healthcare workflow automation.

    At the same time, personalised medicine is reshaping the way treatments are developed and delivered. Rather than applying a one-size-fits-all approach to healthcare, personalised medicine seeks to tailor treatment decisions to the individual characteristics of each patient.

    Artificial intelligence has the potential to play an important role in enabling this shift by helping clinicians interpret complex data and apply clinical guidelines more effectively.

    Importantly, AI should not be viewed as replacing healthcare professionals. Instead, its greatest value lies in supporting clinicians by improving access to information, structuring clinical workflows, and assisting with decision-making.

    The Challenge of NHS Innovation

    Despite the promise of these technologies, the NHS has historically faced challenges in adopting innovation at scale.

    Several structural barriers contribute to this problem.

    Fragmented procurement

    The NHS is a complex system involving multiple organisations responsible for commissioning services and adopting technologies. This fragmentation can make it difficult for new innovations to scale nationally.

    Regulatory complexity

    Digital health technologies must navigate multiple regulatory frameworks, including medical device regulation, data protection requirements, and NHS digital standards. While these frameworks are essential for patient safety, they can create uncertainty for innovators.

    Integration with existing systems

    Healthcare technologies must integrate with existing clinical systems such as electronic patient records and prescribing platforms. Achieving interoperability remains a major challenge.

    Funding and incentives

    Many digital innovations improve clinical efficiency or workflow rather than generating new reimbursable services. As a result, existing commissioning models may not always support the adoption of such technologies.

    The new parliamentary inquiry will examine these issues and consider what changes may be needed to enable innovation to reach patients more effectively.

    The Role of Artificial Intelligence in Clinical Workflows

    While much discussion around AI in healthcare focuses on diagnostics or research, another important application lies in supporting everyday clinical workflows.

    Healthcare professionals increasingly operate under significant time pressure, while clinical guidelines and regulatory requirements continue to grow in complexity.

    AI-enabled systems could assist clinicians by:

    • guiding structured patient assessments
    • analysing patient responses
    • identifying relevant clinical guidance
    • generating consultation documentation
    • supporting safe decision-making.

    By assisting clinicians with these processes, AI tools have the potential to reduce administrative burden while improving the consistency and quality of care.

    The Opportunity in Community-Based Care

    Much of the discussion around healthcare innovation focuses on hospitals or specialist services. However, many opportunities for digital innovation lie within frontline community healthcare settings.

    Across the NHS, community-based services such as general practice and pharmacy are increasingly responsible for delivering accessible clinical care.

    For example, the expansion of services such as Pharmacy First reflects a growing recognition of the clinical role pharmacists can play in managing common conditions and supporting primary care.

    As these services expand, the need for digital tools that support structured consultations, clinical documentation and decision-making will also increase.

    Artificial intelligence may therefore have an important role to play in supporting clinicians across the wider primary care workforce.

    From Innovation to Implementation

    The UK has the scientific expertise, healthcare system and digital capabilities required to become a global leader in AI-enabled healthcare.

    However, achieving this goal will depend not only on developing new technologies, but also on ensuring that innovation can be adopted safely and effectively within real clinical environments.

    The inquiry launched by the House of Lords Science and Technology Committee represents an important opportunity to examine how the NHS can better support the translation of innovation into patient care.

    Ultimately, the challenge facing the NHS is not simply one of innovation.

    It is a question of how quickly and effectively new technologies can be integrated into the healthcare system to benefit both clinicians and patients.

    Artificial intelligence and personalised medicine may represent some of the most significant healthcare innovations of our time. Ensuring that these advances reach the frontline of healthcare delivery will be essential in shaping the future of the NHS.

  • Beyond the Hype: Why AI Like ChatGPT Shouldn’t Give Medical Advice

    Beyond the Hype: Why AI Like ChatGPT Shouldn’t Give Medical Advice

    By Asif Mukhtar, Founder & CEO (Consultant Pharmacist), PharmBot AI

    Artificial intelligence has reshaped the way we access information — including health information. Patients are increasingly turning to large language models (LLMs) like ChatGPT for answers about symptoms, treatments, and even drug interactions.

    But as impressive as these systems are, there’s a crucial boundary that too many people — including healthcare innovators — overlook: AI models are not licensed clinicians, and they must not give medical advice.

    This isn’t just a legal technicality. It’s a matter of safety, accountability, and trust.

    The Line Between Information and Advice

    According to OpenAI’s latest usage policies (November 2025), ChatGPT and similar models are prohibited from providing “tailored advice that requires a licence, such as legal or medical advice.”

    Instead, these systems can only offer general educational information — for example, explaining how hypertension is treated, what PGDs are, or how pharmacists fit into digital healthcare systems.

    That distinction sounds small but it’s critical. Once an AI system begins suggesting what a specific patient should do — what drug to take, what dose, or whether to seek urgent care — it crosses into regulated territory that requires professional accountability.

    And that’s where things can go dangerously wrong.

    Why AI “Advice” Is Still Unsafe

    Even the most advanced LLMs remain probabilistic — they generate plausible text based on patterns in data, not verified medical reasoning.

    They can sound confident while being clinically wrong, misinterpreting symptoms, or overlooking contraindications.

    Studies continue to show that, without human oversight, LLMs can produce unsafe or misleading medical outputs. The technology simply hasn’t reached a level of reliability where autonomous decision-making is acceptable in healthcare.

    This is why regulators, including the UK’s MHRA, the FDA, and the Saudi Food and Drug Authority (SFDA), are moving toward frameworks that require validation, traceability, and clinician oversight for all AI-driven medical software.

    What Responsible Use Looks Like

    In healthcare, AI should augment, not replace, professional judgement.

    That’s the principle we’ve built into AIVAe, PharmBot AI’s flagship assistant. It supports pharmacists and clinical teams by automating documentation, checking compliance, and surfacing information — not by giving unverified medical advice.

    The pharmacist remains in control, the clinical decision remains human, and the AI remains a support system — an intelligent colleague, not an autonomous prescriber.

    This design philosophy is what separates safe, compliant innovation from dangerous experimentation.

    The Role of Pharmacists in the AI Era

    Pharmacists are uniquely positioned to lead the responsible adoption of AI in healthcare.
    Our profession is built on precision, evidence, and accountability — the same qualities that AI must now be trained to respect.

    As we integrate digital tools into practice, we must demand transparency, auditability, and validation.
    AI can streamline our workflows, predict risks, and free us to focus on patient care — but only if it’s implemented within the ethical and professional boundaries that protect patients.

    Final Thought

    AI’s potential in healthcare is extraordinary — but so are its risks.

    The real innovation lies not in pushing AI to “act like a doctor,” but in building systems that make doctors, pharmacists, and nurses smarter, faster, and safer in what they already do.

    At PharmBot AI, that’s the standard we’re holding ourselves to.  Because in healthcare, the line between innovation and irresponsibility is drawn where patient safety begins.